NCT06679101 2026-04-22
DREAMM-10
GlaxoSmithKline
Phase 3 Recruiting
Clinical Trials
12 trialsNCT06232044 2026-03-25
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
Alliance for Clinical Trials in Oncology
Phase 1/2 Recruiting
NCT05091372 2026-03-05
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05847569 2026-02-03
Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
Mayo Clinic
Phase 2 Recruiting
NCT05714839 2026-01-23
DREAMM-20
GlaxoSmithKline
Phase 1/2 Recruiting
NCT05922501 2026-01-14
ISABELA
Massachusetts General Hospital
Phase 2 Recruiting
NCT02343042 2025-12-22
STOMP
Karyopharm Therapeutics Inc
Phase 1/2 Recruiting
NCT05789303 2025-12-22
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
University of Chicago
Phase 2 Recruiting
NCT05002816 2025-10-30
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
Yale University
Phase 1/2 Recruiting
NCT05208307 2025-09-02
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Emory University
Phase 2 Recruiting
NCT05853965 2025-03-30
BELI(E)VE
Universitätsklinikum Hamburg-Eppendorf
Phase 1/2 Recruiting
NCT05060627 2022-09-08
Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide
PETHEMA Foundation
Phase 1/2 Recruiting